Table 2

Surgical procedures, pathology and follow-up outcomes of fifteen patients.

Group

No.

Age (y)

Initial pathology

Surgical type

Recurrent pathology

Postoperative pathology

Myometrial infiltration

Pathology before and after surgery

Postoperative management

Prognosis

Follow-up time(m)

Without retreatment

1

40

AEH

TH

AEH

No lesions

Consistent

NED

9

2

36

AEH

TH

AEH

AEH

Consistent

NED

30

3

37

AEH

TH

AEH

EC IaG1

Upgradea

NED

11

4

32

AEH

Staging surgery

EC IaG1

EC IaG1

Ovarian inclusion cyst (right ovary)

Superficial

Consistent

NED

9

5

24

EC Ia G1

TH

EC IaG1

EC IaG1

Superficial

Consistent

NED

53

6

28

EC IaG1

TH

EC IaG1

EC IaG1

Superficial

Consistent

NED

25

7

32

AEH

Staging surgery

EC IaG1

EC IaG1

Superficial

Consistent

NED

3

Failure to retreatment

8

28

AEH

TH

AEH

AEH

Consistent

NED

70

9

34

AEH

Staging surgery

EC IaG1

EC IaG1; ovarian endometrioid adenocarcinoma IC2 (left ovary)

Superficial

Consistent

Four courses of chemotherapy

NED

5b

10

28

EC IaG1

TH+BSO(preserving partial left ovary)

EC IaG1

EC IaG1; ovarian borderline endometrioid adenocarcinoma (bilateral ovaries)

Consistent

NED

22

11

33

EC IaG1

TH

AEH

EC IaG1

Superficial

Upgradea

NED

118

Fertility completed

12

28

EC IaG1

(CR)subtotal hysterectomy

EC IaG1

No lesions

Consistent

NED

3

Multiple recurrence

13

34

AEH

Staging surgery

EC IaG1

EC IIIc G1

Upgradea

Six courses of chemotherapy

NED

5b

14

33

EC IaG1

Staging surgery (preserving bilateral ovaries)

EC IaG1

EC IaG1

Accord

NED

26

15

36

AEH

TH

EC IaG2

EC Ia

Accord

NED

61

  • TH, total hysterectomy; BSO: bilateral salpingooophoreclomy; EC, endometrial cancer; AEH, atypical endometrial hyperplasia; NED: no evidence of disease.

  • a Upgrade: pathological type upgrades (AEH before while EC after), or pathological stage upgrades.

  • b Follow-up time: duration between last course of chemotherapy and the last follow-up.